



EMMESSAR BIOTECH & NUTRITION LTD

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001
Tel: 66356209/10/11 Fax: 66370190 Email: enquiries@ebnl.org Site: www.ebnl.org
Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

EBN/2017/S-2346

January 20, 2017

Dept. of Corporate Services
The Stock Exchange, Mumbai
1st floor, New Trading Ring, Rotunda Bldg
Phiroze Jeejebhoy Towers, Dalal Street
Fort, Mumbai – 400 001.
Fax No. 22723121 Email ID: corp.relations@bseindia.com

Dear Sir,

Ref: Company Code No. 524768
Sub: Dissemination of Financial Results

We are pleased to inform you that the Board has taken on record the Un-Audited Financial Results of the Company for the quarter ended December 31, 2016, at the meeting of the Board of Directors of the Company, held on Friday, 20th January, 2017, at 4.30 pm.

The above results were reviewed by the audit committee of the Board of Directors.

We are filing the results online in .pdf and excel format alongwith the Limited Review.

Thanking you,

Yours faithfully,
For Emmessar Biotech & Nutrition Ltd




Compliance Officer
Attachment: As above.

EMMESSAR BIOTECH & NUTRITION LTD						
UNAUDITED FINANCIAL RESULTS AS ON 31st DECEMBER 2016						Rs. In Lakhs)
Particulars	Current 3 months ended 31.12.2016	Preceding 3 months ended 30.09.2016	Previous year Corresponding 3 months ended 31.12.2015	Year to date figure for current period ended 31.12.2016	Year to date figure for the previous year ended 31.12.2015	Previous Year ended 31.03.2016
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
PART I						
01) Income from Operations						
(a) Net Sales / Income from operations (Net of Excise Duty)	79.21	6.44	15.81	190.81	146.20	197.44
(b) Other Operating Income	-	-	-	-	-	-
Total Income from Operations (net)	79.21	6.44	15.81	190.81	146.20	197.44
02) Expenditure						
(a) Cost of material consumed	1.12	1.63	1.34	64.58	52.60	53.56
(b) Purchase of Stock-trade	6.61	-	-	12.82	5.48	5.48
(c) Change in inventories of Finished goods	45.26	0.06	1.14	(25.79)	(15.45)	37.16
(d) Employee Benefit Expenses	11.14	8.63	7.28	28.85	22.55	31.10
(e) Depreciation & amortisation of Assets	0.27	0.27	0.37	0.80	1.10	2.72
(f) Other Expenditure	4.86	5.89	5.19	87.96	68.17	69.04
Total Expenditure (a to f)	69.26	16.48	15.32	169.22	134.45	199.06
03) Profit / loss from Operations before Other Income, Finance cost & Exceptional items(1 - 2)	9.95	(10.04)	0.49	21.59	11.75	(1.62)
04) Other Income	32.01	16.57	1.22	64.79	11.29	25.87
05) Profit / loss from ordinary activities before Finance cost & Exceptional Items (3 + 4)	41.96	6.53	1.71	86.38	23.04	24.25
06) Finance cost	-	-	-	-	-	-
07) Profit / loss from ordinary activities after finance cost but before Exceptional Items (5 - 6)	41.96	6.53	1.71	86.38	23.04	24.25
08) Exceptional Items	-	-	-	-	-	(92.17)
09) Profit / (-) Loss from Ordinary Activities Before Tax (7 + 8)	41.96	6.53	1.71	86.38	23.04	(67.92)
10) Tax Expense (Deferred tax)	-	-	-	-	-	21.39
11) Net Profit / (Loss) from Ordinary Activities after Taxation (9 - 10)	41.96	6.53	1.71	86.38	23.04	(46.53)
12) Extraordinary Item (net of tax expense)	-	-	-	-	92.17	-
13) Net Profit / Loss for the period (11-12)	41.96	6.53	1.71	86.38	(69.13)	(46.53)
14) Share of profit / loss of associates	NA	NA	NA	NA	NA	NA
15) Minority Interest	NA	NA	NA	NA	NA	NA
16) Net profit / (loss) for the period (13 + 14 + 15)	41.96	6.53	1.71	86.38	(69.13)	(46.53)
17) Paid-up Equity Share Capital (Face Value of the share)	499.61	499.61	499.61	499.61	499.61	499.61
	10.00	10.00	10.00	10.00	10.00	10.00
18) Reserves excluding Revaluation Reserve (as per Balance Sheet of previous accounting year)	-	-	-	-	-	-
19) Earning per Shares (before extraordinary items)	0.84	0.13	0.03	1.73	0.46	(0.93)
a) Basic & diluted EPS before Extraordinary items for the period, for the year to date & for the previous year						
b) Basic & diluted EPS after Extraordinary items for the period, for the year to date & for the previous year	0.84	0.13	0.03	1.73	(1.38)	(0.93)
PART II						
A. PARTICULARS OF SHAREHOLDINGS						
1) Public Shareholding						
- No. of Shares	2032385	2020385	2076069	2032385	2076069	2020385
- Percentage of Shareholding	40.68	40.44	41.55	40.68	41.55	40.44
2) Promoters & Promoter Group Shareholding						
a) Pledged / Encumbered						
- No. of Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (as % of the total shareholding of the Promoter & Promoter Group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as % of the total Share Capital of the Company)	Nil	Nil	Nil	Nil	Nil	Nil
b) Non Encumbered						
- No. of Shares	2963715	2975715	2920031	2963715	2920031	2975715
- Percentage of Shares (as % of the total shareholding of the Promoter & Promoter Group)	100%	100%	100%	100%	100%	100%
- Percentage of shares (as % of the total Share Capital of the Company)	59.32	59.56	58.45	59.32	58.45	59.56
Particulars Three Months ended 31.12.2016						
B. INVESTORS COMPLAINTS						
Pending at the beginning of the quarter	Nil					
Received during the quarter	Nil					
Disposed off during the quarter	Nil					
Remaining unresolved at the end of the quarter	Nil					

* The above results were reviewed by the Audit Committee of the Board of Directors.
 * The Statutory Auditors have carried out a Limited Review of the results for the quarter ended December 31, 2016
 * The above Un-Audited Results were taken on record at the meeting of the Board of Directors held on 20th January, 2017

Ashok M. Kadakia

By order of the Board
 ASHOK M. KADAKIA
 CHAIRMAN



Mumbai
 20-Jan-17

EMMESSAR BIOTECH & NUTRITION LIMITED						
Quarter ended December 2016 Segment wise Revenue Results and Capital Employed						
						Rs. In Lakhs)
Particulars	Current 3 months ended 31.12.2016	Preceding 3 months ended 30.09.2016	Previous year corresponding 3 months ended 31.12.2015	Year to date figure for current period ended 31.12.2016	Year to date figure for the previous period ended 31.12.2015	Previous year ended 31.03.2016 Audited
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Segment Revenue (Net Sales / Income)						
a. Healthcare	22.70	6.36	4.31	64.41	44.43	48.67
b. Fine Chemicals	56.51	0.08	11.50	126.40	101.77	148.77
c. Others	32.01	16.57	1.22	64.79	11.29	25.87
Total:	111.22	23.01	17.03	255.60	157.49	223.31
Less: Inter Segment Revenue	-	-	-	-	-	-
Net Sales / Income from Operations	111.22	23.01	17.03	255.60	157.49	223.31
2. Segment Results (Profit / Loss) before Tax and Interest						
a. Healthcare	14.92	3.37	2.20	39.10	29.51	31.23
b. Fine Chemicals	9.52	0.09	9.17	40.44	30.54	23.94
c. Others	32.01	16.57	1.22	64.79	11.29	25.87
Total:	56.45	20.03	12.59	144.33	71.34	81.04
Less:						
Interest	-	-	-	-	-	-
Other Unallocable Expenditure (net off Unallocable Income)	14.49	13.50	10.88	57.95	48.30	56.79
Total Profit before Tax	41.96	6.53	1.71	86.38	23.04	24.25
3. Capital Employed (Segment Assets - Segment Liabilities)						
a. Healthcare	14.76	14.19	19.32	14.76	19.32	17.28
b. Fine Chemicals	68.91	98.46	42.29	68.91	42.29	34.78
c. Others	9.32	(50.54)	(57.23)	9.32	(57.23)	(16.94)
Total:	92.99	62.11	4.38	92.99	4.38	35.12

Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature.

The above results were taken on record at a meeting of the Board of Directors held on 20th January, 2017.

Mumbai
20/01/2017

By order of the Board
ASHOK M. KADAKIA
CHAIRMAN



Tel. : 2200 4465, 2206 7440
Fax : 91-22-2200 0649
E-mail : mumbai@vsa.co.in
Website : www.vsa.co.in

V. Sankar Aiyar & Co.
CHARTERED ACCOUNTANTS
2-C, Court Chambers
35, New Marine Lines
Mumbai - 400 020

**LIMITED REVIEW REPORT ON THE UNAUDITED FINANCIAL RESULTS
FOR THE NINE MONTHS ENDED 31ST DECEMBER 2016**

The Board of Directors
Emmessar Biotech & Nutrition Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Emmessar Biotech & Nutrition Limited, for the Nine months ended 31st December 2016. This statement is the responsibility of the Company's management and has been approved by the Board of Directors at its Meeting held on January 20, 2017. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Agreement and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatements.

For V. Sankar Aiyar & Co.
Chartered Accountants
Firm Regn. No.109208W

V. Mohan

(V. Mohan)
Partner

Membership No. 17748

Place: Mumbai

Date: January 20, 2017.